These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31757295)

  • 1. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
    Khaled D; Taylor J; Holzbeierlein J
    Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Intravesical Therapy.
    Brooks NA; O'Donnell MA
    Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
    Haas CR; McKiernan JM
    Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.
    Konety BR; Narayan VM; Dinney CPN
    Urol Clin North Am; 2020 Feb; 47(1):1-4. PubMed ID: 31757292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.
    Peyton CC; Chipollini J; Azizi M; Kamat AM; Gilbert SM; Spiess PE
    World J Urol; 2019 Oct; 37(10):2017-2029. PubMed ID: 30535583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
    Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
    Urology; 2017 May; 103():149-153. PubMed ID: 28163086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
    Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
    Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
    Steinberg RL; Thomas LJ; Nepple KG
    Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
    O'Donnell MA; Krohn J; DeWolf WC
    J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
    Becker REN; Kates MR; Bivalacqua TJ
    Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
    Packiam VT; Johnson SC; Steinberg GD
    Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions.
    Li Y; Youssef SF; Buanz AB
    Eur J Pharmacol; 2022 Jul; 926():175024. PubMed ID: 35580708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
    Crijnen J; De Reijke TM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
    Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.